Research and Development of plant-derived compounds for the therapeutic treatment of cancer patients
Read more >
ORIL is a public, unlisted Australian company that has identified and developed a family of plant-based compounds with a novel mode of action.
Read more >
ORIL has developed a unique platform of anticancer drugs with outstanding market potential.
Read more >
ORIL is a public, unlisted Australian company that has identified and developed a family of plant-based anti-cancer compounds. The Company has an internationally recognised Board, management and advisory teams with a balance of skills, experience and substantial track records in science and business in the biotech and pharma industry.
Read more >ORIL has developed a unique anticancer drug with outstanding market potential. The platform technology is based on a first-in-class mode of action that targets the cancer cell membrane. The current focus is on the treatment of cancer but with potential for other therapeutic applications.
Please view our AGM notice here:
ORIL technology involves the discovery and/or rational design of molecules from plants that have a unique mode of action that preferentially targets cancer cell membranes triggering a series of biochemical events, including anti-angiogenic activity, but importantly leads to cell death by apoptosis.
Read more >Registered Office
Oncology Research International Limited
Level 5, 45 St George Terrace,
Perth WA 6000 Australia